Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates

Advanced Drug Delivery Reviews

Volumn 61, Issue 13, 2009, Pages 1149-1158

  Rihova, Blanka ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Anthracycline antibiotics; Cancer patients; CRP; Doxorubicin HPMA HuIg; Epirubicin HPMA autologous IgG; HPMA; HuIg; Immunostimulation; LAK; NK cells; Polymeric drug; Tumor markers

Indexed keywords

ANTHRACYCLINE ANTIBIOTICS; CANCER PATIENTS; CRP; DOXORUBICIN-HPMA-HUIG; EPIRUBICIN-HPMA-AUTOLOGOUS IGG; HPMA; HUIG; IMMUNOSTIMULATION; LAK; NK CELLS; POLYMERIC DRUG; TUMOR MARKERS;

ANIMALS; ANTIBIOTICS; BLOOD; CELL MEMBRANES; COPOLYMERIZATION; POLYMERS; TOMOGRAPHY;

TUMORS;

ALANINE AMINOTRANSFERASE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CA 15-3 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; DOXORUBICIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER AUTOLOGOUS IMMUNOGLOBULIN G; DOXORUBICIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER HUMAN IMMUNOGLOBULIN; EPIRUBICIN; EPIRUBICIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER AUTOLOGOUS IMMUNOGLOBULIN G; EXEMESTANE; FLUOROURACIL; IFOSFAMIDE; MESNA; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ADJUVANT THERAPY; AGRANULOCYTOSIS; ALLERGIC REACTION; ANGIOSARCOMA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOCHEMISTRY; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG RELEASE; DRUG RESPONSE; DRUG SCREENING; DRUG STABILITY; DYSPNEA; ENZYME BLOOD LEVEL; HOT FLUSH; HUMAN; IMMUNOGENICITY; INDUCED HYPOTHERMIA; LABORATORY TEST; LEUKOCYTE COUNT; LIVER METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RETICULOCYTE COUNT; REVIEW; SIDE EFFECT;

ACRYLAMIDES; ADULT; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HEMANGIOSARCOMA; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MIDDLE AGED; NEOPLASM METASTASIS; POLYMETHACRYLIC ACIDS; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70349998187     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.12.017     Document Type: Review

References (52)

1. Ulbrich K., Pechar M., Etrych T., Jelinkova M., Kovar M., and Rihova B. Polymer carriers for targeted drug delivery and controlled drug release. Mater. Struct. 10 (2003) 3-4
2. Kopecek J., Kopeckova P., Minko T., and Lu Z.R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharmaceutics Biopharm. 50 (2000) 61-81
3. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3 (1992) 175-210
4. Kratz F., Muller I.A., Ryppa C., and Warnecke A. Prodrug strategies in anticancer chemotherapy. Carrier-linked prodrugs. Chem. Med. Chem. 3 (2008) 20-53
5. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of proteins and the antitumor agent. Cancer Res. 6 (1986) 6387-6392
6. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: a key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 (2001) 189-207
7. Omelyanenko V., Kopeckova P., Gentry C., and Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release 53 (1998) 25-37
8. Rihova B., Jelinkova M., Strohalm J., Stastny M., Hovorka O., Plocova D., Kovar M., Draberova L., and Ulbrich K. The anti-proliferative effect of a lectin and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with mouse Thy-1.2 gene. Bioconjug. Chem. 11 (2000) 664-673
9. Rihova B., Jelinkova M., Strohalm J., Subr V., Plocova D., Hovorka O., Novak M., Plundrova D., Germano Y., and Ulbrich K. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab′)2-targeted conjugates and combined therapy with immunomodulators. J. Control. Release 64 (2000) 241-261
10. Minko T., Kopeckova P., Pozharov V., and Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 54 (1998) 223-233
11. Minko T., Kopeckova P., and Kopecek J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control. Release 59 (1999) 133-148
12. Stastny M., Strohalm J., Plocova D., Ulbrich K., and Rihova B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 35 (1999) 459-466
13. Rihova B., Kopeckova P., Strohalm J., Rossmann P., Vetvicka V., and Kopecek J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46 (1988) 100-114
14. Rihova B., Jegorov A., Strohalm J., Matha V., Rossmann P., Fornusek L., and Ulbrich K. Antibody-targeted cyclosporin A. J. Control. Release 19 (1992) 25-39
15. Yeung T.K., Hopewell J.W., Simmonds R.H., Seymour L.W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., and Ulbrich K. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. 29 (1991) 105-111
16. Rihova B., Bilej M., Vetvicka V., Ulbrich K., Strohalm J., Kopecek J., and Duncan R. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Biomaterials 10 (1989) 335-342
17. Rossmann P., Rihova B., Strohalm J., and Ulbrich K. Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug). Folia Microbiol. 42 (1997) 277-287
18. Stastny M., Ulbrich K., Strohalm J., Rossmann P., and Rihova B. Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used. Transplantation 63 (1997) 1818-1827
19. Rihova B., Strohalm J., Hoste K., Jelinkova M., Hovorka O., Kovar M., Plocova D., Sirova M., Stastny M., Schacht E., and Ulbrich K. Immunoprotective therapy with targeted anticancer drugs. Macromol. Symp. 172 (2001) 21-28
20. Rihova B., Strohalm J., Kubackova K., Jelinkova M., Hovorka O., Kovar M., Plocova D., Sirova M., Stastny M., Rozprimova L., and Ulbrich K. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Control. Release 78 (2002) 97-114
21. Rihova B., Strohalm J., Prausova J., Kubackova K., Jelinkova M., Rozprimova L., Sirova M., Plocova D., Etrych T., Subr V., Mrkvan T., Kovar M., and Ulbrich K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control. Release 91 (2003) 1-16
22. Rihova B. Antibody-targeted HPMA copolymer-bound anthracycline antibiotics. Drugs Future 28 (2003) 1189-1210
23. Rihova B., and Kubackova K. Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers. Curr. Pharmaceutical Biotechnol. 4 (2003) 311-322
24. Mrkvan T., Sirova M., Etrych T., Chytil P., Strohalm J., Plocova D., Ulbrich K., and Rihova B. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. J. Control. Release 110 (2005) 119-129
25. Rihova B., Strohalm J., Kovar M., Mrkvan T., Subr V., Hovorka O., Sirova M., Rozprimova L., Kubackova K., and Ulbrich K. Induction of systemic antitumor resistance with targeted polymers. Scand. J. Immunol. 62 (2005) 100-105
26. Sirova M., Strohalm J., Subr V., Plocova D., Mrkvan T., Ulbrich K., and Rihova B. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumor immunity in mice. Cancer Immunol. Immunother. 56 (2007) 35-47
27. M. Kovar, J. Tomala, H. Chmelova, L. Kovar, T. Mrkvan, R. Joskova, Z. Zakostelecka, T. Etrych, J. Strohalm, K. Ulbrich, M. Sirova, B. Rihova, Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin, Cancer Res. 68 (2008) 9875-9883.
28. Shoenfeld Y., and Fishman P. Gamma-globulin inhibits tumor spread in mice. Int. Immunol. 11 (1999) 1247-1252
29. Torchilin V.P., Iakoubov L.Z., and Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 22 (2001) 424-427
30. Rihova B., Strohalm J., Kubackova K., Jelinkova M., Rozprimova L., Sirova M., Plocova D., Mrkvan T., Kovar M., Pokorna J., Etrych T., and Ulbrich K. Drug-HPMA-HuIg conjugates effective against human solid cancer. In: Maeda, et al. (Ed). Polymer Drugs in the Clinical Stage (2003), Kluwer Academic/Plenum Publishers, New York 125-143
31. Steel D., and Whitehead A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today 15 (1994) 81-88
32. Barber M.D., Ross J.A., and Fearon K.C. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr. Cancer 35 (1999) 106-110
33. Nozoe T., Matsumata T., and Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am. J. Clin. Oncol. 23 (2000) 263-266
34. Lumachi F., Brandes A.A., Boccagni P., Polistina F., Favia G., and D' Amico D.F. Long-term follow up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res. 19 (1999) 4485-4489
35. Berois N., Varangot M., Aizen B., Estrugo R., Zarantonelli L., Fernandez P., Krygier G., Simonet F., Barrois E., Muse I., and Osinaga E. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CD19, MUC1 and CEA using RT-PCR. Eur. J. Cancer 36 (2000) 717-723
36. Smith T.R., and Kumar V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 29 (2008) 337-342
37. Cools N., Ponsaerts P., Van Tendeloo V.F., and Berneman Z.N. Regulatory T cells and human disease. Clin. Dev. Immunol. (2007) 891-895
38. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer 5 (2005) 263-274
39. Suzuki F., Pollard R.B., Uchimura S., Munakata T., and Maeda H. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin. Cancer Res. 50 (1990) 3897-3904
40. Lanier L.L., Corliss B., and Phillips J. Arousal and inhibition of human NK cells. Immunol. Rev. 155 (1997) 145-155
41. Montelli T.C., Peracoli M.T., Gabarra R.C., Soares A.M., and Kurokawa C.S. Familial cancer: depressed NK-cell cytotoxicity in healthy and cancer affected members. Arq. Neuropsiquiatr. 59 (2001) 6-10
42. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145 (1991) 185-192
43. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Phase I. Clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5 (1999) 83-94
44. Thomson A.H., Vasey P.A., Murray L.S., Cassidy J., Fraier D., Frigerio E., and Twelves C. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br. J. Cancer 81 (1999) 99-107
45. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin Ch.M., Doran J., David M., Anderson D., Christodoulou Ch., Young A.M., Hesselwood S., and Kerr D.J. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Control. Release 57 (1999) 281-290
46. Rihova B., Veres K., Fornusek L., Ulbrich K., Strohalm J., Vetvicka V., Bilej M., and Kopecek J. Action of polymeric prodrugs based on N-(2-hydroxypropyl)methacrylamide copolymers. II. Body distribution and T-cell accumulation of free and polymer bound [125I]daunomycin. J. Control. Release 10 (1989) 37-49
47. Duncan R., and Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27 (1994) 290-306
48. Rihova B., and Kopecek J. Biological properties of targetable poly[N-(2-hydroxypropyl) methacrylamide]-antibody conjugates. J. Control. Release 2 (1985) 289-310
49. Flanagan P.A., Duncan R., Rihova B., Subr V., and Kopecek J. Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates in A/J and B10 mice. J. Bioact. Compat. Polymers 5 (1990) 151-166
50. Oupicky D., Ulbrich K., and Rihova B. Conjugates of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] with enzymes for protein delivery. J. Bioact. Compat. Polymers 14 (1999) 213-231
51. Subr V., Etrych T., Ulbrich K., Hirano T., Kondo T., Todoroko T., Jelinkova M., and Rihova B. Synthesis and properties of poly[N-(2-hydropxypropyl)methacrylamide] conjugates of superoxide dismutase. J. Bioact. Compat. Polymers 17 (2002) 105-122
52. B. Rihova, L. Kovar, M. Kovar, O. Hovorka, Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics, Trends Biotechnol. 27 (2009) 11-17.